Firsocostat
- Generic Name
- Firsocostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H31N3O8S
- CAS Number
- 1434635-54-7
- Unique Ingredient Identifier
- XE10NJQ95M
- Background
Firsocostat is under investigation in clinical trial NCT02781584 (Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)).
- Associated Conditions
- -
- Associated Therapies
- -
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 109
- Registration Number
- NCT03987074
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Institute for Liver Health - Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Quality Medical Research, PLLC, Nashville, Tennessee, United States
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 74
- Registration Number
- NCT02891408
Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 127
- Registration Number
- NCT02856555
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath